| Enriched clinical annotations |
| For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. |
| Clinical annotation |
Category |
P-value |
Hits |
Hits(%) |
Module hits in category |
Arrays in annotation |
Arrays |
| Cancer and cell line (Lung cancer*) |
Lung cancer* |
1.6e-38 |
133 |
35.3 |
376 |
252 |
1945 |
| Cancer (Lung cancer*) |
Lung cancer* |
1.6e-38 |
133 |
35.3 |
376 |
252 |
1945 |
| Lung tissue, cancer or cell line (Lung cancer*) |
Lung cancer* |
1.3e-36 |
138 |
36.7 |
376 |
276 |
1945 |
| Lung cancer (Lung cancer*) |
Lung cancer* |
5.8e-34 |
123 |
32.7 |
376 |
238 |
1945 |
| Lung cancer or cell line (Lung cancer*) |
Lung cancer* |
5.8e-34 |
123 |
32.7 |
376 |
238 |
1945 |
| Liver tissue (Liver cancer*) |
Liver cancer* |
9.9e-25 |
75 |
30.9 |
242 |
187 |
1945 |
| Liver tissue, cancer or cell line (Liver cancer*) |
Liver cancer* |
5.1e-23 |
75 |
30.9 |
242 |
197 |
1945 |
| Non small cell lung cancer and cell line (Lung cancer*) |
Lung cancer* |
5.5e-21 |
95 |
25.2 |
376 |
205 |
1945 |
| Non small cell lung cancer (Lung cancer*) |
Lung cancer* |
5.5e-21 |
95 |
25.2 |
376 |
205 |
1945 |
| Non-tumor liver tissue (Liver cancer) |
Liver cancer |
1.9e-15 |
54 |
72 |
75 |
76 |
207 |
| Cancer and cell line (Liver cancer) |
Liver cancer |
1.2e-13 |
50 |
100 |
50 |
126 |
207 |
| Hepatitis infected liver (Liver cancer*) |
Liver cancer* |
6.4e-13 |
52 |
21.4 |
242 |
156 |
1945 |
| B cells (Leukemia) |
Leukemia |
2.1e-12 |
34 |
91.8 |
37 |
62 |
141 |
| Diffuse large B cell lymphoma - DLBCL (B lymphoma) |
B lymphoma |
5.1e-11 |
39 |
95.1 |
41 |
126 |
245 |
| Diffuse large B cell lymphoma tumor or cell line (B lymphoma) |
B lymphoma |
7.7e-10 |
39 |
95.1 |
41 |
134 |
245 |
| Primary blood mononuclear cells (Leukemia) |
Leukemia |
1.3e-08 |
17 |
45.9 |
37 |
21 |
141 |
| Cell line (Breast cancer) |
Breast cancer |
3.8e-08 |
19 |
55.8 |
34 |
30 |
152 |
| Bone marrow (Leukemia) |
Leukemia |
1.6e-07 |
17 |
45.9 |
37 |
23 |
141 |
| Normal tissue (Liver cancer) |
Liver cancer |
2.8e-07 |
14 |
18.6 |
75 |
14 |
207 |
| Liver cancer cell line (Liver cancer) |
Liver cancer |
3.2e-07 |
10 |
20 |
50 |
10 |
207 |
| Acute lymphocytic leukemia (Leukemia) |
Leukemia |
4.8e-07 |
40 |
95.2 |
42 |
99 |
149 |
| Breast cancer cell line (Breast cancer) |
Breast cancer |
5.4e-07 |
13 |
38.2 |
34 |
17 |
152 |
| Activated B like DLBCL (B lymphoma) |
B lymphoma |
6.4e-07 |
16 |
39.0 |
41 |
30 |
245 |
| Lymphocytes (Leukemia) |
Leukemia |
1.7e-06 |
35 |
94.5 |
37 |
91 |
141 |
| Cell line (Liver cancer) |
Liver cancer |
2.8e-06 |
10 |
20 |
50 |
11 |
207 |
| Lymphoma or lymphoma cell line (B lymphoma) |
B lymphoma |
8.0e-06 |
39 |
95.1 |
41 |
167 |
245 |
| Female hormonal cancer cell line (Breast cancer) |
Breast cancer |
1.1e-05 |
11 |
32.3 |
34 |
15 |
152 |
| Metastasis (Liver cancer) |
Liver cancer |
1.2e-05 |
9 |
18 |
50 |
10 |
207 |
| Adenocarcinoma (Breast cancer*) |
Breast cancer* |
1.6e-05 |
30 |
12.3 |
242 |
112 |
1945 |
| Breast cancer (Breast cancer*) |
Breast cancer* |
1.6e-05 |
30 |
12.3 |
242 |
112 |
1945 |
| Cancer (Breast cancer*) |
Breast cancer* |
1.6e-05 |
30 |
12.3 |
242 |
112 |
1945 |
| Female hormonal cancer (Breast cancer*) |
Breast cancer* |
1.6e-05 |
30 |
12.3 |
242 |
112 |
1945 |
| Centroblasts (Various tumors) |
Various tumors |
1.7e-05 |
5 |
26.3 |
19 |
5 |
154 |
| GC B like DLBCL (Various tumors) |
Various tumors |
1.7e-05 |
5 |
26.3 |
19 |
5 |
154 |
| Breast tissue or cancer (Breast cancer*) |
Breast cancer* |
1.8e-05 |
31 |
12.8 |
242 |
118 |
1945 |
| Female hormonal tissue or cancer (Breast cancer*) |
Breast cancer* |
1.8e-05 |
31 |
12.8 |
242 |
118 |
1945 |
| Cancer (Liver cancer) |
Liver cancer |
4.0e-05 |
40 |
80 |
50 |
115 |
207 |
| B. petrussis 537 stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
5.4e-05 |
5 |
22.7 |
22 |
5 |
144 |
| Stage T1 (Lung cancer) |
Lung cancer |
6.0e-05 |
93 |
89.4 |
104 |
153 |
195 |
| Lung carcinoid (Lung cancer) |
Lung cancer |
0.0001 |
18 |
13.0 |
138 |
20 |
276 |
| Female hormonal cancer or cell line (Breast cancer*) |
Breast cancer* |
0.0002 |
30 |
12.3 |
242 |
127 |
1945 |
| Breast cancer or cell line (Breast cancer*) |
Breast cancer* |
0.0002 |
30 |
12.3 |
242 |
128 |
1945 |
| After doxorubicin chemotherapy (Breast cancer) |
Breast cancer |
0.0002 |
15 |
88.2 |
17 |
21 |
38 |
| GC B like DLBCL (B lymphoma) |
B lymphoma |
0.0003 |
18 |
43.9 |
41 |
53 |
245 |